FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2185-2186 May 15, 2008 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Triptans are serotonin-receptor agonists used in the treatment of migraine headaches. When administered in combination with certain drugs, such as selective serotonin-reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), triptans may precipitate the serotonin syndrome, a potentially life-threatening condition characterized by a triad of clinical manifestations — changes in mental status, autonomic hyperactivity, and neuromuscular abnormalities.^1,2 The cause of the serotonin syndrome is related to altered serotonin synthesis, release, reuptake, metabolism, or receptor agonism.³ We investigated whether triptan monotherapy is associated with the serotonin syndrome by searching for such cases in the Food and Drug Administration's Adverse . . . [Full Text of this Article]

Related Letters:

More on Serotonin Syndrome Associated with Triptan Monotherapy
Evans R. W., Soldin O. P.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:870-871, Aug 21, 2008. Correspondence

This article has been cited by other articles:

• Evans, R. W., Soldin, O. P. (2008). More on Serotonin Syndrome Associated with Triptan Monotherapy. NEJM 359: 870-871 [Full Text]